The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
Open accessAbstract
Importance: Uncertainty remains about how aggressively to treat early multiple sclerosis. High-efficacy disease-modifying therapies (DMTs) are often reserved for individuals expressing poor prognostic features at baseline. Objective: To analyze long-term outcomes in a population-based cohort according to initial treatment strategy. Design, Setting and Participants: In this cohort study, data were derived from January 1998 to December 2016, and analysis was performed in January 2017. From a total of 720 patients prescribed a DMT, 592 (82%) were included in analysis. Reasons for exclusion were first treated elsewhere or privately (n = 39), clinical trial participant (n = 25), and insufficient clinical data (n = 45). Exposures: Patients were classified according to first-line treatment strategy: high-efficacy (early intensive treatment [EIT]) or moderate-efficacy DMT (escalation [ESC]). Main Outcomes and Measures: Primary outcome was 5-year change in Expanded Disability Status Scale score. Secondary outcome was time to sustained accumulation of disability (SAD). Models were adjusted for sex, age at treatment, year of starting DMT, and escalation to high-efficacy treatment in the ESC group. Results: Mean (SD) age of 592 patients at symptom onset was 27.0 (9.4) years. Mean (SD) 5-year change in Expanded Disability Status Scale score was lower in the EIT group than the ESC group (0.3 [1.5] vs 1.2 [1.5]); this remained significant after adjustment for relevant covariates (β = -0.85; 95% CI, -1.38 to -0.32; P = .002). Median (95% CI) time to SAD was 6.0 (3.17-9.16) years for EIT and 3.14 (2.77-4.00) years for ESC (P = .05). For those within the ESC group who escalated to high-efficacy DMT as second-line treatment, median (95% CI) time to SAD was 3.3 years (1.8-5.6; compared with EIT group log-rank test P = .08). After adjustment for relevant covariates, there was no difference in hazard of SAD between the groups. However, 60% of those who escalated to high-efficacy DMTs were observed to develop SAD while still receiving initial moderate-efficacy treatment before escalation. Conclusions and Relevance: In a real-life setting, long-term outcomes were more favorable following early intensive therapy vs first-line moderate-efficacy DMT. Contemporary surveillance strategies and escalation protocols may be insufficiently responsive. This finding is particularly relevant as patients in real-world practice are typically selected for an EIT approach to therapy on the basis of clinical and radiological features predictive of a poor outcome. These data support the need for a prospective randomized clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni, G., Turner, B., Gnanapavan, S., Offiah, C., Schmierer, K., & Marta, M. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.04.006 · Cited by 338
Cited by
Myelin-oligodendrocyte glycoprotein antibody-associated disease
Marignier, R., Hacohen, Y., Cobo-Calvo, A., Pröbstel, A.-K., Aktas, O., Alexopoulos, H., Amato, M.-P., Asgari, N., Banwell, B., Bennett, J., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00218-0 · Cited by 543
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
Cobo-Calvo, A., Tur, C., Otero-Romero, S., Carbonell-Mirabent, P., Ruiz, M., Pappolla, A., Villacieros Alvarez, J., Vidal-Jordana, A., Arrambide, G., Castilló, J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207664 · Cited by 65
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
Metadata
- Authors
- Harding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., & Tallantyre, E.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-01
- Volume
- 76
- Issue
- 5
- Pages
- 536
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2916478209
- Cited by
- 366
- References
- 27
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. https://app.cochat.ai/papers/10.1001/jamaneurol.2018.4905
- The paper
- Harding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., & Tallantyre, E. (2019). Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2018.4905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.